UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 0614, 2025

EVOKE PHARMA, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-36075	20-8447886
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

420 Stevens Avenue, Suite 230
Solana Beach, California		92075
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code:  858 345-1494

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	EVOK	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 82.0102 ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On August 614, 2025, Evoke Pharma, Inc. ~~(the~~issued ~~“Company”) announced the official issuance of~~ a ~~new~~press ~~U.S.~~release ~~patent~~announcing ~~related to~~ its ~~product~~financial ~~GIMOTI®.~~results ~~The~~for ~~patent, U.S. Patent No. 12,377,064, covers~~ the ~~use~~three ofand ~~intranasal~~six-month ~~metoclopramide~~periods inended ~~patients~~June ~~with moderate to severe symptoms of gastroparesis~~30, ~~and has now been issued by the United States Patent and Trademark Office ("USPTO")~~2025. ~~The~~A ~~patent~~copy ~~term~~of ~~has been extended by~~ the ~~USPTO~~press torelease ~~November~~is ~~2038,~~attached ~~due~~hereto toas ~~patent~~Exhibit ~~term adjustments~~99.1 ~~The~~and ~~Company~~is ~~plans~~incorporated toherein ~~list~~by ~~this newly issued patent in the FDA’s Orange Book~~reference.

~~Safe~~In ~~Harbor~~accordance ~~Statement~~with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

~~The~~Item ~~Company cautions you that statements included in this report that are not a description of historical facts are forward-looking statements~~9.01 InFinancial ~~some~~Statements cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and ~~expectations~~Exhibits. These forward-looking statements include statements regarding: the timing of updated listing in the Orange Book. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: the Company’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in the Company’s periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

~~SIGNATURES~~(d) Exhibits

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Exhibit No.		Description
99.1		Press Release issued on August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

			Evoke Pharma, Inc.
Date:	August 6, 2025	By:	/s/ Matthew J. D'Onofrio
			Name: Maatthew J. D'OnofrioTitle: Chief Executive Officer and Director

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			EVOKE PHARMA, INC.

Date:	August 14, 2025	By:	/s/ Matthew J. D'Onofrio
			Name: Matthew J. D'Onofrio Title: Chief Executive Officer and Director

Filing Compare · Evoke Pharma Inc